{"entity":{"id":"nct07405476","kind":"trial","name":"Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment","aka":[],"tldr":"A phase 2 trial of zanidatamab in colorectal cancer, run by Emory University, now recruiting.","summary":"Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment is a phase 2, interventional study registered as NCT07405476 by Emory University, with a registry enrolment figure of 38 participants, started 2026-04-07 and due to reach its primary completion in 2028-12-18. Interventions recorded: Zanidatamab; Resection; Patient Observation; Echocardiography Test; Multigated Acquisition Scan; Endoscopic Procedure; Computed Tomography; Magnetic Resonance Imaging; Biospecimen Collection; Biopsy Procedure; Digital Rectal Examination; Electronic Health Record Review. Conditions listed: Colon Carcinoma; Colorectal Carcinoma; Rectal Carcinoma; Stage I Colon Cancer AJCC v8; Stage I Colorectal Cancer AJCC v8; Stage I Rectal Cancer AJCC v8; Stage II Colon Cancer AJCC v8; Stage II Colorectal Cancer AJCC v8; Stage II Rectal Cancer AJCC v8; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8. Primary outcome: Rate of Complete and Major Pathologic Regression (Cohort 1); Radiologic Response (Cohort 2); Tumor Regression Grades (Cohort 2). Colorectal eligibility wording from the registry: \"* Histologically or cytologically confirmed colon and/or rectal cancer planned for curative intent treatment at gastrointestinal clinics of Emory University's Winship Cancer Institute and collaborating centers\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07405476","url":"https://clinicaltrials.gov/study/NCT07405476"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","her2-amplified-colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["zanidatamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07405476","phase":"2","setting":"A Phase II Clinical Trial of Neoadjuvant Zanidatamab for HER2+ Localized Colorectal Cancer","sponsor":"Emory University","enrolled":38,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07405476/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"drug":[{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}